J&J posts early phase 1b results for pasritamig in metastatic prostate cancer

Johnson & Johnson announced preliminary results from a Phase 1b study evaluating pasritamig, a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specific antigen responses and sustained PSA reductions, supporting continued development and advancement into Phase 3 studies. The results were presented for the first time at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium. “Based on these findings, we are increasingly confident in the potential of pasritamig to meaningfully improve outcomes for people with prostate cancer,” said Charles Drake, Vice President, Prostate Cancer and Cross Cancer Immuno-Oncology, Johnson & Johnson. “The ability to combine pasritamig with docetaxel, where prior approaches in the field have fallen short, gives us a strong foundation for Phase 3 development. What we’re seeing with this combination, including deep and durable PSA responses, underscores the promise of this combination immunotherapy approach and our commitment to advancing innovation that can make a difference for patients.”